https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22648 Wed 22 May 2019 14:50:34 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13691 Wed 11 Apr 2018 17:01:07 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28397 Wed 11 Apr 2018 15:14:13 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13693 Wed 11 Apr 2018 14:32:54 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28923 Wed 11 Apr 2018 10:33:05 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27446 Tue 13 Oct 2020 19:11:18 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17471 Sat 24 Mar 2018 08:04:07 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19533 95% of the identified indication bias. Slightly lower relapse incidence was found among patients treated with glatiramer acetate or subcutaneous interferon β-1a relative to intramuscular interferon β-1a and interferon β-1b (p≤0.001). No differences in 12-month confirmed progression of disability were observed. Conclusion: Small but statistically significant differences in relapse outcomes exist among the injectable immunomodulators. MSBase is sufficiently powered to identify these differences and reflects practice in tertiary MS centres. While the present study controlled indication, selection and attrition bias, centre-dependent variance in data quality was likely.]]> Sat 24 Mar 2018 08:02:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19821 Sat 24 Mar 2018 07:56:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20329 Sat 24 Mar 2018 07:55:11 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28472 2 than ≤2. Two-point progression was uncommon for EDSS score of <2 and more common at EDSS score of 4. Conclusions: EDSS rank stability increases with disease duration, probably due to reduced relapses and less random variation in later disease. After 4 years duration, EDSS rank was highly predictive of EDSS rank 5 years later. Risk of progression by 10 years was highly dependent on EDSS score at 5 years duration. We confirm the utility of EDSS ranking to predict 5-year outcome in individuals 4 years after disease onset.]]> Sat 24 Mar 2018 07:39:35 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28467 Sat 24 Mar 2018 07:39:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28805 P < 10⁻¹²). However, the female-to-male ratio in patients with relapse-onset multiple sclerosis and zero relapses in any given year was double that of the patients with primary progressive multiple sclerosis. Patient age was a more important determinant of decline in relapse incidence than disease duration (P < 10⁻¹²). Females are predisposed to higher relapse activity than males. However, this difference does not explain the markedly lower female-to-male sex ratio in primary progressive multiple sclerosis. Decline in relapse activity over time is more closely related to patient age than disease duration.]]> Sat 24 Mar 2018 07:38:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30101 Sat 24 Mar 2018 07:37:59 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30262 p [signed-rank] < 0.0001), a 64% reduction in the rate of first relapse (hazard ratio [HR] 0.36, 95% confidence interval [CI] 0.28–0.47; p < 0.001), and a 27% reduction in the rate of discontinuation (HR 0.73, 95% CI 0.58–0.93; p = 0.01), compared with first-line IFN-β/GA therapy. Confirmed disability progression and area under the Expanded Disability Status Scale–time curve analyses were not significant. Similar relapse and treatment persistence results were observed in each of the higher disease activity subgroups. Conclusions: This study provides Class IV evidence that first-line natalizumab for RRMS improves relapse and treatment persistence outcomes compared to first-line IFN-β/GA. This needs to be balanced against the risk of progressive multifocal leukoencephalopathy in natalizumab-treated patients. Classification of evidence: This study provides Class IV evidence that first-line natalizumab for RRMS improves relapse rates and treatment persistence outcomes compared to first-line IFN-β/GA.]]> Sat 24 Mar 2018 07:33:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29942 -23). A reciprocal relationship was seen for ambient ultraviolet radiation (UVR), with a significantly increasing AAO for patients with MS per each quartile increment of ambient UVR (p=1.56×10^-17). We found that the AAO of female patients was ~5 months earlier than male patients (p=0.002). AAO of progressive-onset patients with MS were ~9 years later than relapsing-onset patients (p=1.40×10^-265). Conclusions: An earlier AAO in higher latitude regions was found in this worldwide European-descent cohort and correlated inversely with variation in latitudinal UVR. These results suggest that environmental factors which act at the population level may significantly influence disease severity characteristics in genetically susceptible populations.]]> Sat 24 Mar 2018 07:31:01 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24856 -22). On-therapy relapses carried greater burden than off-therapy relapses. Cumulative treatment exposure was independently associated with lower EDSS at 10 years (coeff=-0.86, p=1.3x10^-9). Furthermore, pregnancies were also independently associated with lower EDSS scores over the 10-year observation period (coeff=-0.36, p=0.009).We provide evidence of long-term treatment benefit in a large registry cohort, and provide evidence of long-term protective effects of pregnancy against disability accrual. We demonstrate that high annualized relapse rate, particularly on-treatment relapse, is an indicator of poor prognosis.]]> Sat 24 Mar 2018 07:11:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23959 Sat 24 Mar 2018 07:10:07 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25306 Mon 06 Mar 2023 17:55:37 AEDT ]]>